Neil Mcfarlane News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neil mcfarlane. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neil Mcfarlane Today - Breaking & Trending Today

Zevra to Present Data from KP1077 Phase 2 Trial in IH at SLEEP

Zevra's CEO updates shareholders on recent milestones, including the completion of a phase 2 trial for idiopathic hypersomnia. ....

Neil Mcfarlane , Zevra Therapeutics Inc , Corium Inc , Drug Administration , Zevra Therapeutics , Therapeutics Inc , Adrian Quartel , One Zevra ,

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript

Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2. ....

Sumant Kulkarni , Neil Mcfarlane , Christal Mickle , Jonathan Aschoff , Oren Livnat , Laduane Clifton , Joshua Schafer , Nichol Ochsner , Corporate Communications For Zevra Therapeutics , Drug Enforcement Administration , Business Development , Unidentified Company Representative , Zevra Therapeutics Inc , Innovation Mc Group , Zevra Therapeutics , Call Transcript March , Financial Results , Vice President , Investor Relations , Corporate Communications , Zevra Therapeutic , Investor Release , Risk Factors , Chief Executive Officer , Chief Financial Officer , Chief Commercial Officer ,

Zevra Reports Positive Phase 2 Results for IH Drug Candidate

Zevra Therapeutics announced positive topline results from its phase 2 clinical trial evaluating KP1077 for idiopathic hypersomnia (IH). ....

Putilich Dreamstime , Christopher Drake , Neil Mcfarlane , Drug Administration , Zevra Therapeutics , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Brain Fog ,

Zevra Therapeutics Announces Top-Line Data from the Phase 2

KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study . ....

United States , Christopher Drake , Neil Mcfarlane , Nichol Ochsner , Ignacio Guerrero Ros , Adannag Alexander , Zevra Therapeutics Inc , Us Drug Enforcement Agency , Drug Administration , Exchange Commission , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Principal Investigator , Chief Executive Officer , Brain Fog , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Nasdaq Zvra , Zevra Therapeutics ,

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Nichol Ochsner , Adannag Alexander , Ignacio Guerrero Ros , Christopher Drake , Neil Mcfarlane , Us Drug Enforcement Agency , Drug Administration , Exchange Commission , Zevra Therapeutics Inc , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Principal Investigator , Chief Executive Officer , Brain Fog , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,